Fairvalue-Calculator Fairvalue-Calculator
EN DE

Shanghai Serum Bio-Technology Co (688163) Fair Value & Analysis

Healthcare · CN · Market cap 4.9B CNY

Price¥44.87
Fair Value¥7.95
Upside-82.3%
Quality95/100
Evidence: High Range ¥5.57 – ¥7.95

Fair value as of: Jun 24, 2026

Analysis

Shanghai Serum Bio-Technology Co (688163) currently trades at ¥44.87, while our model-based Fair Value estimate is ¥7.95 — implying the stock looks roughly 82.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Shanghai Serum Bio-Technology Co., Ltd. engages in the research, development, production, operation, and sales of antitoxin and antiserum products in China. It offers equine anti-tetanus immunoglobulin, anti-venin, and anti-rabies serum products. The company was founded in 1999 and is based in Shanghai, China.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Shanghai Serum Bio-Technology Co (688163) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥7.95 versus a price of ¥44.87 — about −82% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 688163?
Our 21-model fair value for Shanghai Serum Bio-Technology Co is ¥7.95 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥44.87.
What is the quality score of 688163?
Shanghai Serum Bio-Technology Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.